Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Autolus Therapeutics (AUTL) over the last 3 years, with Sep 2025 value amounting to $2.1 million.

  • Autolus Therapeutics' Depreciation and Depletion rose 10.53% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 10.81%. This contributed to the annual value of $7.6 million for FY2024, which is 15.15% up from last year.
  • Per Autolus Therapeutics' latest filing, its Depreciation and Depletion stood at $2.1 million for Q3 2025, which was down 0.00% from $2.1 million recorded in Q2 2025.
  • Autolus Therapeutics' Depreciation and Depletion's 5-year high stood at $2.1 million during Q2 2025, with a 5-year trough of $1.4 million in Q3 2023.
  • For the 3-year period, Autolus Therapeutics' Depreciation and Depletion averaged around $1.9 million, with its median value being $1.9 million (2024).
  • In the last 5 years, Autolus Therapeutics' Depreciation and Depletion decreased by 22.22% in 2023 and then spiked by 35.71% in 2024.
  • Autolus Therapeutics' Depreciation and Depletion (Quarterly) stood at $1.6 million in 2022, then increased by 12.50% to $1.8 million in 2023, then rose by 11.11% to $2.0 million in 2024, then climbed by 10.53% to $2.1 million in 2025.
  • Its Depreciation and Depletion stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.